MARKSANS

Marksans Pharma Share Price

₹307.70 +2.35 (0.77%)

21 Nov, 2024 14:21

SIP TrendupStart SIP in MARKSANS

Start SIP

Performance

  • Low
  • ₹297
  • High
  • ₹310
  • 52 Week Low
  • ₹130
  • 52 Week High
  • ₹329
  • Open Price₹305
  • Previous Close₹305
  • Volume1,540,848

Investment Returns

  • Over 1 Month + 9.74%
  • Over 3 Month + 40.2%
  • Over 6 Month + 85.35%
  • Over 1 Year + 124.34%
SIP Lightning

Smart Investing Starts Here Start SIP with Marksans Pharma for Steady Growth!

Invest Now

Marksans Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40.2
  • PEG Ratio
  • 2.4
  • Market Cap Cr
  • 13,944
  • P/B Ratio
  • 6.7
  • Average True Range
  • 14.37
  • EPS
  • 7.66
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 5
  • RSI
  • 59.15
  • MFI
  • 80.06

Marksans Pharma Financials

Marksans Pharma Technicals

EMA & SMA

Current Price
₹307.70
+ 2.35 (0.77%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹294.55
  • 50 Day
  • ₹280.17
  • 100 Day
  • ₹253.71
  • 200 Day
  • ₹216.66

Resistance and Support

307.75 Pivot Speed
  • R3 324.40
  • R2 319.65
  • R1 312.50
  • S1 300.60
  • S2 295.85
  • S3 288.70

What's your outlook on Marksans Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Marksans Pharma Ltd. is a global pharmaceutical company engaged in the research, development, and manufacturing of generic drugs. It offers a wide range of pharmaceutical formulations, serving key therapeutic areas such as pain management, cardiovascular, and gastrointestinal.

Marksans Pharma has an operating revenue of Rs. 2,378.68 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 19% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 50% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 89 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Marksans Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results & Final Dividend
2024-02-13 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2024-09-17 FINAL Rs.0.60 per share(60%)Final Dividend
2023-06-07 FINAL Rs.0.50 per share(50%)Final Dividend

Marksans Pharma F&O

Marksans Pharma Shareholding Pattern

43.87%
3.02%
10.43%
0%
26.76%
15.92%

About Marksans Pharma

  • NSE Symbol
  • MARKSANS
  • BSE Symbol
  • 524404
  • Chairman & Managing Director
  • Mr. Mark Saldanha
  • ISIN
  • INE750C01026

Similar Stocks to Marksans Pharma

Marksans Pharma FAQs

Marksans Pharma share price is ₹307 As on 21 November, 2024 | 14:07

The Market Cap of Marksans Pharma is ₹13943.8 Cr As on 21 November, 2024 | 14:07

The P/E ratio of Marksans Pharma is 40.2 As on 21 November, 2024 | 14:07

The PB ratio of Marksans Pharma is 6.7 As on 21 November, 2024 | 14:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23